Related references
Note: Only part of the references are listed.Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial
Julie Schjodtz Hansen et al.
PHARMACEUTICALS (2023)
Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain A Systematic Review and Meta-analysis
Filip Gedin et al.
JAMA NETWORK OPEN (2022)
Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization
Peter T. Doohan et al.
AAPS JOURNAL (2021)
The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial
Julie Schjodtz Hansen et al.
BRAIN SCIENCES (2021)
Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews
R. Andrew Moore et al.
PAIN (2021)
Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials
Emma Fisher et al.
PAIN (2021)
The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial
Shlomo Almog et al.
EUROPEAN JOURNAL OF PAIN (2020)
The Placebo Effect in Pain Therapies
Luana Colloca
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59 (2019)
Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
Angela K. Birnbaum et al.
EPILEPSIA (2019)
The REDCap consortium: Building an international community of software platform partners
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2019)
The pharmacokinetics and the pharmacodynamics of cannabinoids
Catherine J. Lucas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases
Valerio Chiurchiu et al.
PROGRESS IN NEUROBIOLOGY (2018)
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Delta 9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis
Guido van Amerongen et al.
CLINICAL THERAPEUTICS (2018)
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Sophie A. Millar et al.
FRONTIERS IN PHARMACOLOGY (2018)
Cannabinoids and Pain: New Insights From Old Molecules
Sonja Vuckovic et al.
FRONTIERS IN PHARMACOLOGY (2018)
Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology
Jacob Atsmon et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Sensitive Determination of Cannabinoids in Whole Blood by LC-MS-MS After Rapid Removal of Phospholipids by Filtration
Lambert K. Sorensen et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2017)
Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes
Ryan Vandrey et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2017)
Cannabis and Pain: A Clinical Review
Kevin P. Hill et al.
CANNABIS AND CANNABINOID RESEARCH (2017)
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
Uwe K. Zettl et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics
Hoai-Thu Thai et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2014)
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users
Ryan Vandrey et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance
W. Byon et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
John Peter Zajicek et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2012)
Plasma Cannabinoid Pharmacokinetics following Controlled Oral Delta(9)-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration
Erin L. Karschner et al.
CLINICAL CHEMISTRY (2011)
The placebo response in clinical trials: more questions than answers
Paul Enck et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2011)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids
A. Strougo et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Clinical trial outcome in neuropathic pain - Relationship to study characteristics
Jennifer Katz et al.
NEUROLOGY (2008)
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors
G. Pryce et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Human cannabinoid pharmacokinetics
Marilyn A. Huestis
CHEMISTRY & BIODIVERSITY (2007)
Δ9-Tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids
Robert S. Goodivin et al.
THERAPEUTIC DRUG MONITORING (2006)
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
J Zajicek et al.
LANCET (2003)
Pharmacokinetics and pharmacodynamics of cannabinoids
F Grotenhermen
CLINICAL PHARMACOKINETICS (2003)
Share Paper
